We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+80.2%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$709M
AUM Growth
+$128M
Cap. Flow
+$13.2M
Cap. Flow %
1.86%
Top 10 Hldgs %
89.06%
Holding
20
New
4
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$71.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$24.6M
3
MRUS
Merus
MRUS
+$24.3M
4
KOD icon
Kodiak Sciences
KOD
+$12.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$9.43M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$58.6M
2
ONC
BeOne Medicines Ltd
ONC
+$51.6M
3
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$16.6M
4
GERN icon
Geron
GERN
+$15.4M
5
TRVI icon
Trevi Therapeutics
TRVI
+$1.28M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$12.3B
$169M 23.76%
2,344,980
+333,333
+17% +$24.6M
NUVL
2
DELISTED
Nuvalent
NUVL
$122M 17.15%
2,884,492
– –
IMGN
3
DELISTED
Immunogen Inc
IMGN
$114M 16.04%
+6,029,592
New +$71.2M
ELVN icon
4
Enliven Therapeutics
ELVN
$3.77B
$43.4M 6.11%
2,124,625
+199,687
+10% +$4.04M
COGT icon
5
Cogent Biosciences
COGT
$6.91B
$42.1M 5.94%
3,558,975
+800,000
+29% +$9.18M
MRUS
6
DELISTED
Merus
MRUS
$39M 5.5%
1,482,405
+1,107,970
+296% +$24.3M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.18B
$32.6M 4.59%
1,369,623
– –
ARGX icon
8
argenx
ARGX
$55.6B
$28.7M 4.04%
73,526
– –
TYRA icon
9
Tyra Biosciences
TYRA
$1.85B
$24.1M 3.4%
1,416,998
– –
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$17.9M 2.52%
2,040,000
– –
ATXS
11
DELISTED
Astria Therapeutics
ATXS
$15.8M 2.23%
1,901,397
– –
KOD icon
12
Kodiak Sciences
KOD
$2.62B
$13.7M 1.93%
+1,985,245
New +$12.1M
DBVT
13
DBV Technologies
DBVT
$823M
$13.4M 1.89%
706,496
– –
TRVI icon
14
Trevi Therapeutics
TRVI
$2.57B
$12.4M 1.75%
5,190,360
-506,155
-9% -$1.28M
KNSA icon
15
Kiniksa Pharmaceuticals
KNSA
$4.89B
$9.92M 1.4%
+704,459
New +$9.43M
VRNA
16
DELISTED
Verona Pharma
VRNA
$8.07M 1.14%
381,939
-2,745,490
-88% -$58.6M
SYRE icon
17
Spyre Therapeutics
SYRE
$8.69B
$4.26M 0.6%
+378,422
New +$1.79M
GERN icon
18
Geron
GERN
$949M
– –
-7,104,358
Closed -$15.4M
ONC
19
BeOne Medicines Ltd
ONC
$33.8B
– –
-239,443
Closed -$51.6M
THRX
20
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-1,865,671
Closed -$16.6M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q2 2023 Portfolio in Review

As of Q2 2023, Fairmount Funds Management held 20 positions worth $709M, up 22% from $581M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Fairmount Funds Management's Q2 2023 filing shows 4 new, 4 increased, 2 reduced and 3 closed positions. Its largest new stake was Immunogen Inc: 6,029,592 shares worth $114M. The largest sale was Verona Pharma, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Fairmount Funds Management's largest Q2 2023 buy was Immunogen Inc: 6,029,592 shares worth $114M.
  • Fairmount Funds Management added most to Axsome Therapeutics in Q2 2023, an estimated $24.6M increase.
  • Fairmount Funds Management's biggest Q2 2023 reduction was Verona Pharma, cutting an estimated $58.6M.
  • Fairmount Funds Management fully exited BeOne Medicines Ltd in Q2 2023, selling an estimated $51.6M.
  • Fairmount Funds Management's ten largest holdings make up 89% of its $709M portfolio in Q2 2023.
  • Fairmount Funds Management opened 4 new positions and closed 3 in Q2 2023.
  • Fairmount Funds Management's portfolio value rose 22% quarter-over-quarter to $709M.

Based on Fairmount Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.